Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
MeSH Number(s)
D12.776.157.530.400.175.125
D12.776.543.550.425.175.125
D12.776.543.585.400.175.125
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Harvard Catalyst Profiles by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 5 | 5 |
| 1993 | 0 | 5 | 5 |
| 1994 | 0 | 5 | 5 |
| 1995 | 2 | 2 | 4 |
| 1996 | 5 | 0 | 5 |
| 1997 | 5 | 2 | 7 |
| 1998 | 6 | 1 | 7 |
| 1999 | 6 | 0 | 6 |
| 2000 | 6 | 4 | 10 |
| 2001 | 8 | 3 | 11 |
| 2002 | 7 | 2 | 9 |
| 2003 | 4 | 4 | 8 |
| 2004 | 9 | 5 | 14 |
| 2005 | 5 | 5 | 10 |
| 2006 | 5 | 1 | 6 |
| 2007 | 7 | 4 | 11 |
| 2008 | 6 | 3 | 9 |
| 2009 | 11 | 7 | 18 |
| 2010 | 6 | 8 | 14 |
| 2011 | 8 | 3 | 11 |
| 2012 | 5 | 4 | 9 |
| 2013 | 4 | 2 | 6 |
| 2014 | 6 | 2 | 8 |
| 2015 | 7 | 6 | 13 |
| 2016 | 10 | 5 | 15 |
| 2017 | 9 | 3 | 12 |
| 2018 | 5 | 2 | 7 |
| 2019 | 9 | 7 | 16 |
| 2020 | 7 | 3 | 10 |
| 2021 | 8 | 10 | 18 |
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022 03; 10(3):267-277.
-
A growing trend: CFTR modulators for cystic fibrosis lung transplant recipients. J Heart Lung Transplant. 2022 02; 41(2):127-128.
-
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825.
-
Cystic Fibrosis and the Cells of the Airway Epithelium: What Are Ionocytes and What Do They Do? Annu Rev Pathol. 2022 01 24; 17:23-46.
-
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021 08; 18(8):1397-1405.
-
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103.
-
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532.
-
A deep learning approach to identify gene targets of a therapeutic for human splicing disorders. Nat Commun. 2021 06 07; 12(1):3332.
-
Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition. Nat Med. 2021 05; 27(5):806-814.
-
The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261.